摘要
目的观察氟桂利嗪与尼莫地平对偏头痛患者预后的影响。方法 2018年1月-2019年9月时间段内于该院接受诊治的86例偏头痛患者为对象展开研究,由随机双盲法分成两组,即对照组43例、实验组43例;对照组住院期间接受氟桂利嗪疗法,实验组住院期间接受氟桂利嗪+尼莫地平疗法,比较分析两组患者的临床治疗效果、偏头痛发作频率,并参考视觉模拟评分法(VAS)评价偏头痛发作状态下的疼痛评分,最后对比两组患者的不良反应发生率。结果实验组临床治疗有效率为93.02%,明显高于对照组的74.42%,差异有统计学意义(χ^2=5.460,P<0.05);实验组偏头痛发作频率(0.51±0.17)次/月、VAS评分(1.52±0.26)分低于对照组(1.81±0.24)次/月、(3.07±0.44)分,差异有统计学意义(t=28.985、19.887,P<0.05);实验组不良反应发生率2.33%低于对照组的23.26%,差异有统计学意义(χ^2=8.444,P<0.05)。结论偏头痛患者经氟桂利嗪、尼莫地平联合疗法治疗之后,可以改善其临床症状,减少发作频率与疼痛程度,此外,不良反应发生风险较低,可以为患者预后提供安全保障,具有临床推广价值。
Objective To observe the effects of flunarizine and nimodipine on the prognosis of migraine patients.Methods The 86 patients with migraine who were diagnosed and treated in the hospital from January 2018 to September 2019 were studied as subjects,and were divided into two groups by random double-blind method,namely the control group(43 cases)and the experimental group(43 cases);the control group received flunarizine therapy during hospitalization,and the experimental group received flunarizine+ni-modipine therapy during hospitalization.The clinical treatment effect and migraine attack frequency of the two groups were compared and analyzed,and the visual analog score(VAS)was referenced to evaluate the pain score under migraine attacks,and finally com-pares the incidence of adverse reactions between the two groups of patients.Results The effective rate of clinical treatment in the ex-perimental group was 93.02%,which was significantly higher than 74.42%in the control group.The difference was statistically signifi-cant(χ^2=5.460,P<0.05);the frequency of migraine attacks in the experimental group(0.51±0.17)times per month,VAS score(1.52±0.26)points lower than the control group(1.81±0.24)times per month,(3.07±0.44)points,the difference was statistically significant(t=28.985,19.887,P<0.05);the adverse reaction rate of the experimental group was 2.33%lower than 23.26%in the control group,there were statistically significant differences between the groups(χ^2=8.444,P<0.05).Conclusion After flunarizine and nimodipine combination therapy in migraine patients,their clinical symptoms can be improved,the frequency of attacks and the degree of pain can be re-duced.In addition,the risk of adverse reactions is low,which can provide a safety guarantee for the prognosis of patients,with clinical promotion value.
作者
方齐
宫志成
FANG Qi;GONG Zhi-cheng(Department of Neurology,Rushan People's Hospital,Rushan,Shandong Province,264500 China)
出处
《世界复合医学》
2020年第8期159-161,共3页
World Journal of Complex Medicine
